Investor Relations

Investor Home

Corporate Profile
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit
Stock Quote
NASDAQ CM :  MLND (Common Stock)
0.00 (0.00%)
Stock chart for: MLND.O.  Currently trading at $10.10 with a 52 week high of $17.40 and a 52 week low of $6.77.
Data as of 01/22/19 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Upcoming Eventsmore »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.